** CSL CSL.AX slips 15.5% to A$179.77 so far this week; set for biggest weekly drop since week ended August 22

** Biotech major no longer targetting spin-off of its vaccine division, Seqirus, in FY26 due to heightened volatility in U.S. influenza vaccine market

** Says demerger will resume when market conditions can support maximisation of shareholder value

** CSL last down 0.1%, takes YTD losses to 36.2%

(Reporting by Keshav Singh Chundawat in Bengaluru)

((Keshav.singhchundawat@thomsonreuters.com))